CEP-32496BRAF(V600E)inhibitor,highly potent CAS# 1188910-76-0 |
- CEP-32496
Catalog No.:BCC1079
CAS No.:1188910-76-0
- Sorafenib
Catalog No.:BCN2174
CAS No.:284461-73-0
- Vemurafenib (PLX4032, RG7204)
Catalog No.:BCC1269
CAS No.:918504-65-1
- BRAF inhibitor
Catalog No.:BCC1436
CAS No.:918505-61-0
- PLX-4720
Catalog No.:BCC1280
CAS No.:918505-84-7
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 1188910-76-0 | SDF | Download SDF |
PubChem ID | 56846693 | Appearance | Powder |
Formula | C24H22F3N5O5 | M.Wt | 517.46 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | GTPL7880;CEP32496;CEP32496 | ||
Solubility | DMSO : 50 mg/mL (96.63 mM; Need ultrasonic) | ||
Chemical Name | 1-[3-(6,7-dimethoxyquinazolin-4-yl)oxyphenyl]-3-[5-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-3-yl]urea | ||
SMILES | CC(C)(C1=CC(=NO1)NC(=O)NC2=CC(=CC=C2)OC3=NC=NC4=CC(=C(C=C43)OC)OC)C(F)(F)F | ||
Standard InChIKey | DKNUPRMJNUQNHR-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C24H22F3N5O5/c1-23(2,24(25,26)27)19-11-20(32-37-19)31-22(33)30-13-6-5-7-14(8-13)36-21-15-9-17(34-3)18(35-4)10-16(15)28-12-29-21/h5-12H,1-4H3,(H2,30,31,32,33) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | CEP-32496 is a highly potent inhibitor of BRAF(V600E/WT) and c-Raf with Kd of 14 nM/36 nM and 39 nM, also potent to Abl-1, c-Kit, Ret, PDGFRβ and VEGFR2, respectively; insignificant affinity for MEK-1, MEK-2, ERK-1 and ERK-2. IC50 value: 14 nM/36 nM(Kd,BRAF(V600E/WT) ); 39 nM (Kd,C-Raf) Target: B-Raf/C-Raf CEP-32496 is a potent BRAF inhibitor in an in vitro binding assay for mutated BRAF(V600E) (K(d) BRAF(V600E) = 14 nM) and in a mitogen-activated protein (MAP)/extracellular signal-regulated (ER) kinase (MEK) phosphorylation (pMEK) inhibition assay in human melanoma (A375) and colorectal cancer (Colo-205) cell lines (IC(50) = 78 and 60 nmol/L). In vitro, CEP-32496 has multikinase binding activity at other cancer targets of interest; however, it exhibits selective cellular cytotoxicity for BRAF(V600E) versus wild-type cells. |
CEP-32496 Dilution Calculator
CEP-32496 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.9325 mL | 9.6626 mL | 19.3252 mL | 38.6503 mL | 48.3129 mL |
5 mM | 0.3865 mL | 1.9325 mL | 3.865 mL | 7.7301 mL | 9.6626 mL |
10 mM | 0.1933 mL | 0.9663 mL | 1.9325 mL | 3.865 mL | 4.8313 mL |
50 mM | 0.0387 mL | 0.1933 mL | 0.3865 mL | 0.773 mL | 0.9663 mL |
100 mM | 0.0193 mL | 0.0966 mL | 0.1933 mL | 0.3865 mL | 0.4831 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
CEP-32496 is a highly potent and orally efficacious V600E mutant BRAF, WT BRAF and c-Raf inhibitor with Kd values of 14 nM, 36 nM and 39 nM, respectively.
In addition to BRAFV600E, CEP-32496 has exhibited high binding affinity for both wild-type BRAF and related CRAF, as well as certain receptor tyrosine kinases of known therapeutic utility, such as Abl-1, c-Kit, Ret, PDGFR-β, and VEGFR-2. However, CEP-32496 proved selective for the RAF members of the MAPK signal transduction pathway, as no significant affinity was observed for other key kinases of the MAPK pathway, including MEK-1, MEK-2, ERK-1, and ERK-2. This suggests that the observed cellular activity was driven primarily through inhibition of BRAFV600E, which is further supported by the observation that CEP-32496 exhibited selective cytotoxicity for tumor cell lines expressing mutant BRAF versus those expressing wild-type BRAF [1].
Oral administration of CEP-32496 to Colo-205 tumor xenograft-bearing mice resulted in significant inhibition of pMEK in tumor cell lysates [1].
References:
[1] Rowbottom MW1, Faraoni R, Chao Q, Campbell BT, Lai AG, Setti E, Ezawa M, Sprankle KG, Abraham S, Tran L, Struss B, Gibney M, Armstrong RC,Gunawardane RN, Nepomuceno RR, Valenta I, Hua H, Gardner MF, Cramer MD, Gitnick D, Insko DE, Apuy JL, Jones-Bolin S, Ghose AK, Herbertz T, Ator MA,Dorsey BD, Ruggeri B, Williams M, Bhagwat S, James J, Holladay MW. Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2 -methylpropan- 2-yl) isoxazol-3-yl) urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E. J Med Chem. 2012 Feb 9;55(3):1082-105. doi: 10.1021/jm2009925. Epub 2012 Jan 23.
- KN-93 Phosphate
Catalog No.:BCC5638
CAS No.:1188890-41-6
- ABT 702 dihydrochloride
Catalog No.:BCC5905
CAS No.:1188890-28-9
- NBQX
Catalog No.:BCC6624
CAS No.:118876-58-7
- Anti-Inflammatory Peptide 1
Catalog No.:BCC1006
CAS No.:118850-71-8
- Ustusolate C
Catalog No.:BCN6755
CAS No.:1188398-15-3
- Ustusol C
Catalog No.:BCN6757
CAS No.:1188398-13-1
- 15,16-Di-O-acetyldarutoside
Catalog No.:BCN6071
CAS No.:1188282-02-1
- 16-O-Acetyldarutigenol
Catalog No.:BCN6070
CAS No.:1188282-01-0
- 9-Hydroxydarutigenol
Catalog No.:BCN6069
CAS No.:1188282-00-9
- 7-Hydroxydarutigenol
Catalog No.:BCN6068
CAS No.:1188281-99-3
- ent-14,16-Epoxy-8-pimarene-3,15-diol
Catalog No.:BCN6067
CAS No.:1188281-98-2
- Ac-Leu-OH
Catalog No.:BCC2967
CAS No.:1188-21-2
- Alstoyunine E
Catalog No.:BCN4782
CAS No.:1188932-15-1
- Fmoc-D-Allo-Ile-OH
Catalog No.:BCC3508
CAS No.:118904-37-3
- Lettowienolide
Catalog No.:BCN8038
CAS No.:1189105-39-2
- Denudaquinol
Catalog No.:BCN8035
CAS No.:1189105-40-5
- Balanophonin
Catalog No.:BCN6072
CAS No.:118916-57-7
- 5-(3-Hydroxypropyl)-7-methoxybenzofuran
Catalog No.:BCN1606
CAS No.:118930-92-0
- 1,3-Dihydroxy-4-methoxy-10-methylacridin-9(10H)-one
Catalog No.:BCN1605
CAS No.:1189362-86-4
- (S,S)-2,6-Bis(4-isopropyl-2-oxazolin-2-yl)pyridine
Catalog No.:BCC8402
CAS No.:118949-61-4
- Ethyl ganoderate J
Catalog No.:BCN3486
CAS No.:1189555-95-0
- Mephedrone hydrochloride
Catalog No.:BCC6183
CAS No.:1189726-22-4
- Fumitremorgin C
Catalog No.:BCC7507
CAS No.:118974-02-0
- 1-O-Deacetyl-2alpha-hydroxykhayanolide E
Catalog No.:BCN1604
CAS No.:1189801-51-1
[(11)C-carbonyl]CEP-32496: radiosynthesis, biodistribution and PET study of brain uptake in P-gp/BCRP knockout mice.[Pubmed:24930831]
Bioorg Med Chem Lett. 2014 Aug 1;24(15):3574-7.
CEP-32496 is a novel, orally active serine/threonine-protein kinase B-raf (BRAF) (V600E) kinase inhibitor that is being investigated in clinical trials for the treatment of some cancers in patients. In this study, we developed [(11)C-carbonyl]CEP-32496 as a novel positron emission tomography (PET) probe to study its biodistribution in the whole bodies of mice. [(11)C]CEP-32496 was synthesized by the reaction of 5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-amine hydrochloride (1.HCl) with [(11)C]phosgene, followed by treatment with 3-(6,7-dimethoxyquinozolin-4-yloxy)aniline (2). Small-animal PET studies with [(11)C]CEP-32496 indicated that radioactivity levels (AUC0-90 min, SUVxmin) accumulated in the brains of P-gp/BCRP knockout mice at a 8-fold higher rate than in the brains of wild-type mice.
CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity.[Pubmed:22319199]
Mol Cancer Ther. 2012 Apr;11(4):930-41.
Mutations in the BRAF gene have been identified in approximately 7% of cancers, including 60% to 70% of melanomas, 29% to 83% of papillary thyroid carcinomas, 4% to 16% colorectal cancers, and a lesser extent in serous ovarian and non-small cell lung cancers. The V600E mutation is found in the vast majority of cases and is an activating mutation, conferring transforming and immortalization potential to cells. CEP-32496 is a potent BRAF inhibitor in an in vitro binding assay for mutated BRAF(V600E) (K(d) BRAF(V600E) = 14 nmol/L) and in a mitogen-activated protein (MAP)/extracellular signal-regulated (ER) kinase (MEK) phosphorylation (pMEK) inhibition assay in human melanoma (A375) and colorectal cancer (Colo-205) cell lines (IC(50) = 78 and 60 nmol/L). In vitro, CEP-32496 has multikinase binding activity at other cancer targets of interest; however, it exhibits selective cellular cytotoxicity for BRAF(V600E) versus wild-type cells. CEP-32496 is orally bioavailable in multiple preclinical species (>95% in rats, dogs, and monkeys) and has single oral dose pharmacodynamic inhibition (10-55 mg/kg) of both pMEK and pERK in BRAF(V600E) colon carcinoma xenografts in nude mice. Sustained tumor stasis and regressions are observed with oral administration (30-100 mg/kg twice daily) against BRAF(V600E) melanoma and colon carcinoma xenografts, with no adverse effects. Little or no epithelial hyperplasia was observed in rodents and primates with prolonged oral administration and sustained exposure. CEP-32496 benchmarks favorably with respect to other kinase inhibitors, including RAF-265 (phase I), sorafenib, (approved), and vemurafenib (PLX4032/RG7204, approved). CEP-32496 represents a novel and pharmacologically active BRAF inhibitor with a favorable side effect profile currently in clinical development.
Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropa n-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E.[Pubmed:22168626]
J Med Chem. 2012 Feb 9;55(3):1082-105.
The Ras/RAF/MEK/ERK mitogen-activated protein kinase (MAPK) signaling pathway plays a central role in the regulation of cell growth, differentiation, and survival. Expression of mutant BRAF(V600E) results in constitutive activation of the MAPK pathway, which can lead to uncontrolled cellular growth. Herein, we describe an SAR optimization campaign around a series of quinazoline derived BRAF(V600E) inhibitors. In particular, the bioisosteric replacement of a metabolically sensitive tert-butyl group with fluorinated alkyl moieties is described. This effort led directly to the identification of a clinical candidate, compound 40 (CEP-32496). Compound 40 exhibits high potency against several BRAF(V600E)-dependent cell lines and selective cytotoxicity for tumor cell lines expressing mutant BRAF(V600E) versus those containing wild-type BRAF. Compound 40 also exhibits an excellent PK profile across multiple preclinical species. In addition, significant oral efficacy was observed in a 14-day BRAF(V600E)-dependent human Colo-205 tumor xenograft mouse model, upon dosing at 30 and 100 mg/kg BID.